Citi analyst Andrew Baum predicts Blenrep will be a standard...
Citi analyst Andrew Baum predicts Blenrep will be a standard care for refractory multiple myeloma patients for the next five years, assuming the DREAMM-8 trial meets its primary goal.
GSK Raised to Buy at Citi After Cancer Drug Data
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3203Followers
0Following
7974Visitors
Follow